A randomized phase I/IIa study to evaluate the safety and efficacy of SNK01 (non-genetically modified autologous natural killer cells with enhanced cytotoxicity) plus pembrolizumab in patients with stage IV non-small cell lung cancer.

Eo Jin Kim,Dae-Hyun Ko,Wonjun Ji,Jin Kyung Rho,Jae Cheol Lee,Paul Y. Song,Chang-Min Choi

A randomized phase I/IIa study to evaluate the safety and efficacy of SNK01 (non-genetically modified autologous natural killer cells with enhanced cytotoxicity) plus pembrolizumab in patients with stage IV non-small cell lung cancer.

2020

Eo Jin Kim
Dae-Hyun Ko
Wonjun Ji
Jin Kyung Rho
Jae Cheol Lee
Paul Y. Song
Chang-Min Choi

3037Background: Despite the increased promise of checkpoint inhibitors in the treatment of lung cancer, the overall response rate is approximately 30% with up to 30% moderate to severe side effects...

Keywords:

Cytotoxicity
Genetically modified organism
Stage IV non-small cell lung cancer
in patient
Pembrolizumab
Pathology
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations